Related Experiment Video
Updated: Jun 26, 2026

Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies
Published on: March 2, 2018
INCA033989: the first shot on goal for MPNs?
Camelia Benlabiod1, Bethan Psaila1,2
1University of Oxford.
Abstract:
In this issue of Blood, Reis et al1 identify a monoclonal antibody, INCA033989, that selectively targets mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs), inhibiting its oncogenic activity without affecting normal hematopoiesis.
Insights
Researchers discovered a new antibody, INCA033989, that targets mutant calreticulin in myeloproliferative neoplasms. This antibody inhibits cancer growth without harming healthy blood cells, offering a potential new therapy for MPNs.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Myeloproliferative neoplasms (MPNs) are a group of blood cancers.
- Mutant calreticulin (mutCALR) is a key driver in certain MPNs.
- Targeting oncogenic proteins is a therapeutic strategy in cancer treatment.
Purpose of the Study:
- To identify and characterize a novel therapeutic agent for MPNs.
- To investigate the selective targeting of mutant calreticulin (mutCALR).
- To assess the impact of targeting mutCALR on normal hematopoiesis.
Main Methods:
- Identification and characterization of monoclonal antibody INCA033989.
- In vitro and in vivo studies to assess antibody efficacy and specificity.
- Evaluation of effects on mutant calreticulin activity and downstream signaling.
- Assessment of impact on normal hematopoietic stem and progenitor cells.
Main Results:
- Monoclonal antibody INCA033989 selectively binds to and inhibits mutant calreticulin.
- Targeting mutCALR with INCA033989 reduces oncogenic activity in MPN models.
- Normal hematopoiesis remains unaffected by INCA033989 treatment.
- INCA033989 demonstrates potential as a targeted therapy for MPNs.
Conclusions:
- INCA033989 is a promising therapeutic antibody for MPNs harboring calreticulin mutations.
- Selective inhibition of mutCALR offers a targeted approach with a favorable safety profile.
- This discovery opens new avenues for treating specific MPN subtypes.
Related Concept Videos
Projectile Motion
When an object falls under gravity and has no horizontal...
Projectile Motion: Example
When we speak of the range (R) of a projectile on level...
Postsynaptic Potential (PSP)
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
Shotcrete
First Impression
Projectile Motion

